Evidence map›Paper›PMID 32071043›Full record

ArticleAntimicrobial agents and chemotherapy2020

Christopher A Rice, Luis Fernando Lares-Jiménez, Fernando Lares-Villa, Dennis E Kyle

Open access · greenAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.1field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Drug susceptibility of a clinical isolate ofAntimicrobial agents and chemotherapy · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Antiamoebic Properties of Metabolites againstAntibiotics (Basel, Switzerland) · 2022
    Article
  7. Discovery of New Chemical Tools againstPharmaceuticals (Basel, Switzerland) · 2021
    Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Christopher A RiceCenter for Tropical and Emerging Global Diseases, University of Georgia, Athens, Georgia, USA christopher.rice@uga.edu dennis.kyle@uga.edu.ORCID 0000-0003-0672-9604
Luis Fernando Lares-JiménezPrograma de Doctorado en Ciencias en Biotecnología, Departamento de Ciencias Agronómicas y Veterinarias, Instituto Tecnológico de Sonora, Obregon City, Sonora, Mexico.
Fernando Lares-VillaPrograma de Doctorado en Ciencias en Biotecnología, Departamento de Ciencias Agronómicas y Veterinarias, Instituto Tecnológico de Sonora, Obregon City, Sonora, Mexico.
Dennis E KyleCenter for Tropical and Emerging Global Diseases, University of Georgia, Athens, Georgia, USA christopher.rice@uga.edu dennis.kyle@uga.edu.ORCID 0000-0002-0238-965X
Sonora Institute of Technology · MXUniversity of Georgia · US

Funding

Lead Optimization of Bis-benzimidazole Analogs for Pathogenic Free-living AmoebaeR21AI119787 · NIAID · UNIVERSITY OF SOUTH FLORIDA · PI KYLE, DENNIS E · 2015 to 2016
$425k
NIAID NIH HHS R21 AI119787
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AmebiasisAmebicidesAnimalsAntimalarialsBalamuthia mandrillarisComputer SimulationDose-Response Relationship, DrugDrug DiscoveryDrug Evaluation, PreclinicalFemalePapioPregnancyAmebicidesAntimalarialsantiparasitic agentsBalamuthiaBalamuthia amoebic encephalitisBalamuthia mandrillarisdrug discoverygranulomatous amoebic encephalitisMMV Malaria BoxMMV Pathogen Boxphenotypic screening

Identifiers

PMID32071043
PMCPMC7179646
OpenAlexW3006405365

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.